Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma

Devansu Tewari; Bahman Saffari; Carol Cowan; Anita C. Wallick; M. Zach Koontz; Bradley J. Monk

doi:10.1016/j.ygyno.2006.04.025

Back

Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma

Journal article

Peer reviewed

Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma

Devansu Tewari, Bahman Saffari, Carol Cowan, Anita C. Wallick, M. Zach Koontz and Bradley J. Monk

Gynecologic oncology, Vol.102(3), pp.421-424

09/01/2006

DOI: https://doi.org/10.1016/j.ygyno.2006.04.025

PMID: 16797679

Abstract

ET-743

Metastatic uterine leiomyosarcoma

Trabectiden

Yondelis

The ongoing search for more effective agents in the treatment of uterine leiomyosarcomas is warranted because of the poor prognosis related to these tumors. A case of advanced, recurrent and refractory uterine leiomyosarcoma is presented that responded to trabectedin (ET-743) 1.2 mg/m2 intravenously over 24 h every 3 weeks after failing four prior regimens. A durable objective response lasting at least 8 months was documented. Trabectedin (ET-743) has activity in uterine leiomyosarcoma and warrants further investigation.

Metrics

2 Record Views

Details

Title: Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma
Creators: Devansu Tewari - University of California, Irvine
Bahman Saffari - University of California, Irvine
Carol Cowan - University of California, Irvine
Anita C. Wallick - University of California, Irvine
M. Zach Koontz - University of California, Irvine
Bradley J. Monk - University of California, Irvine
Publication Details: Gynecologic oncology, Vol.102(3), pp.421-424
Publisher: Elsevier Inc
Identifiers: 991005968889902656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article

Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma

Abstract

Related links

Metrics

Details